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B-Myb acts as a repressor of human COL1A1 collagen gene expression
by interacting with Sp1 and CBF factors in scleroderma fibroblasts
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We investigated the role of B-Myb, a cell-cycle-regulated transcription factor, in the expression of the α1 (I) pro-collagen gene
(COL1A1) in scleroderma fibroblasts. Scleroderma or SSc (systemic sclerosis) is a fibrotic disease characterized by excessive
production of extracellular matrix components, especially type I
collagen. Northern-blot analysis showed an inverse relationship
between COL1A1 mRNA expression and that of B-Myb during
exponential cell growth and during quiescence in human SSc
fibroblasts. Overexpression of B-Myb in SSc fibroblasts was correlated with decreased COL1A1 mRNA expression. Transient
transfections localized the down-regulatory effect of B-Myb to a
region containing the proximal 174 bp of the COL1A1 promoter
that does not contain B-Myb consensus binding sites. Gel-shift
analysis, using nuclear extracts from normal and SSc fibroblasts
transfected with B-Myb, showed no differences in DNA–protein
complex formation when compared with the nuclear extracts from

mock-transfected cells. However, we found that B-Myb decreases Sp1 (specificity protein 1) and CBF (CCAAT-binding
factor) binding for their specific sites localized in the 174 bp
COL1A1 proximal promoter. These results were also confirmed
using B-Myb-immunodepleted nuclear extracts. Furthermore,
immunoprecipitation assays using SSc nuclear extracts demonstrated a physical interaction of B-Myb with Sp1 and CBF transcription factors, and also an interaction between Sp1 and CBF.
In addition, by employing full-length or deleted B-Myb cDNA
construct, we found that B-Myb down-regulates the COL1A1
proximal promoter through its C-terminal domain. Thus these
results suggest that B-Myb may be an important factor in the
pathway(s) regulating collagen production in SSc fibroblasts.

INTRODUCTION

repress the promoter activity of the genes encoding type I [19],
type V [20] and type VI collagens [21].
Type I collagen is a heterotrimeric molecule consisting of two
α1 (I) chains and one α2 (I) chain and is produced in tissues
such as skin and bone by fibroblasts and osteoblasts [22–25].
Scleroderma or SSc (systemic sclerosis) is an auto-immune disease of unknown origin characterized by skin thickening, fibrosis
and microvascular changes often associated with progressive
internal organ involvement [26,27]. Excessive accumulation of
extracellular matrix components in affected tissues is a central
event in the pathogenesis of SSc [22]. Fibroblasts cultured from
SSc skin biopsies exhibit higher than normal expression levels of
matrix components, such as type I collagen, a phenotype that
is maintained during several passages [23,24]. Previous work
using bovine aortic SMCs (smooth-muscle cells) demonstrated
that type I collagen is down-regulated by the overexpression
of the transcription factor B-Myb [19,20]. Moreover, whereas
B-Myb mRNA levels have been found to increase during cellular
proliferation and to decrease in quiescent SMC cells, type I
collagen expression, instead, varies inversely with the cellular
growth state [19,20]. The ability of B-Myb to down-regulate
collagen gene expression led us to investigate the potential role
of B-Myb in the control of type I collagen (COL1A1 gene)
expression in SSc fibroblasts. We have previously found that
a short region of − 174 bp of the COL1A1 proximal promoter
was responsible for most of the transcriptional activity of the
COL1A1 gene in vitro in normal and in SSc fibroblasts [28]. We

B-Myb belongs to a family of transcription factors that includes
two other members, A-Myb and c-Myb, which are important in
controlling cell proliferation and differentiation [1]. Unlike other
members of the family, B-Myb is expressed ubiquitously and its
biological activity is regulated at multiple levels in a cell-cycledependent manner. Expression of B-Myb is significantly induced
during the G1–S transition and S-phase of the cell cycle and downmodulated in resting and differentiated cells [2,3]. The fact that
B-Myb is highly expressed during S-phase suggests that it modulates transcription at this stage of the cell cycle. Several studies
have reported that B-Myb expression promotes cell proliferation,
whereas extrinsic expression of B-Myb results in the suppression
of cell differentiation induced by different agents [4–6]. B-Myb
is regulated at the protein level by phosphorylation [7,8] and
acetylation [9] in a cell-type-specific fashion. It has been shown
that a sequence-specific MBS (Myb-binding site) is not always
necessary for B-Myb function [8]. In fact, an increasing body of
evidence has indicated the dependence of B-Myb activity on its
interaction with other nuclear factors such as cyclin D1 [10] and
poly(ADP-ribose) polymerase [11]. The effects of B-Myb on gene
promoter activity are complex. B-Myb transactivates the promoter
of several genes, many of which are involved in cell proliferation
and survival, such as DNA topoisomerase IIα [12], c-myc [13],
Hsp70 [14], B-Myb itself [15], apolipoprotein J [16], Bcl2 [17]
and murine surfactant Protein A [18]. In contrast, B-Myb can
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further demonstrated that Sp1 (specificity protein 1) and CBF
(CCAAT binding factor), also called NF-Y or CP1, probably play
a central role in the increased expression of COL1A1 seen in
dermal fibroblasts from patients with SSc. Specifically, we have
shown that these transcription factors interact with the proximal
promoter region of COL1A1 and that there is increased DNA
binding activity to the Sp1 [28] and CBF cis elements [25] in SSc
nuclear extracts when compared with normal fibroblasts.
Here we show that B-Myb decreases the expression of the
human COL1A1 gene in normal and SSc fibroblasts. We localize
the down-regulatory effect of B-Myb to the − 174 bp of the
COL1A1 proximal promoter and show that B-Myb partially inhibits Sp1 and CBF binding for their consensus sites in the proximal
promoter region of the gene. We also found that a physical interaction of B-Myb with Sp1 and CBF factors occurs, which may
be responsible for the down-regulatory effects on COL1A1 expression.
EXPERIMENTAL
Cell culture and time-course conditions

Dermal fibroblast cell lines were established from patients with
diffuse SSc of recent onset and rapid progression, as previously
reported [25,28]. All patients studied were observed at the
Scleroderma Center of Thomas Jefferson University and fulfilled
the American College of Rheumatology (formerly, the American
Rheumatism Association) criteria for the classification of SSc
[29]. All studies were approved by the IRB. Only untreated cases
were studied to avoid spurious results caused by the various therapeutic agents. In all cases, the cell lines were obtained from fullthickness skin biopsy samples that were surgically excised from
the leading edge of clinically apparent SSc lesions [28]. Control
fibroblasts were obtained from age- and sex-matched individuals
undergoing surgical procedures for unrelated purposes. For all
studies, only early-passage fibroblasts (< 8) were examined to
avoid the possibility of phenotypic changes during extended subculture. Cells were routinely maintained in DMEM (Dulbecco’s
modified Eagle’s medium) supplemented with 10 % (v/v) FBS
(foetal bovine serum; Invitrogen, Carlsbad, CA, U.S.A.), 1 %
vitamins, 2 mM L-glutamine and antibiotics, and incubated at
37 ◦ C in a 5 % CO2 humidified atmosphere. For serum stimulation
studies, cells were plated at an initial density of 5 × 105 cells in
100 mm dishes and grown in DMEM supplemented with 10 %
FBS for 1 day (subconfluent cultures). Cultures were then serumdepleted for 48 h by culture in 0.1 % FBS–DMEM and then
stimulated with 10 % FBS for 0, 24 and 48 h. Total RNA was
isolated at the indicated times and analysed as described below.
Transient transfections of human dermal fibroblasts

Cells were transfected by using the lipid-based transfection
reagents supplied in the FuGene 6 kit (Roche, Indianapolis, IN,
U.S.A.). For CAT (chloramphenicol acetyltransferase) assays,
cells were plated at 70 % confluency in 60 mm dishes and cotransfected with 1 µg of CAT-containing constructs (− 5.3, − 2.3,
− 675, − 369, − 174 and − 84 bp) of the human COL1A1 promoter [30] and 0.5 µg of several CMV (cytomegalovirus) constructs
containing either the full-length B-Myb cDNA or mutated forms
(N/B-Myb, Eco/B-Myb or Sca/B-Myb). Empty CMV vector
was used as a negative control. The cells were harvested 48 h
after transfection. The protein concentration of the extracts was
determined using the Bio-Rad reagent (Bio-Rad, Hercules, CA,
U.S.A.). For studies of the effect of B-Myb overexpression on
COL1A1 mRNA levels, cells at 70 % confluency in 100 mm
dishes were transfected with either 2 µg/plate of human CMV
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B-Myb expression vector for 48 h or empty CMV vector as control. Additionally, in the same studies in normal and SSc fibroblasts, we also co-transfected 2 µg/plate of the Capture-TecTM
pHook-1 plasmid (Invitrogen) to isolate transfected cells. Transfection of the pHook plasmid into cells results in the expression
of a single-chain antibody (sFv) that recognizes a specific hapten,
which is displayed on the surface of transfected cells. These were
then isolated from the untransfected cells by binding to haptencoated magnetic beads. The selection procedure was carried out
following the manufacturer’s instructions (Invitrogen).
β-Galactosidase and CAT assays

For all experiments, transfection efficiency was corrected by
co-transfecting with 0.2 µg of CMV vector containing the
Escherichia coli β-galactosidase cDNA (ClonTech, Palo Alto,
CA, U.S.A.), assaying for β-galactosidase activity according to
the manufacturer’s instructions (ClonTech). After each sample
was normalized for β-galactosidase activity, 2 µl of chloramphenicol (55.0 mCi/mmol 1,2-14 C; Amersham Biosciences,
Piscataway, NJ, U.S.A.) and 15 µl (3.5 mg/ml) of acetyl-CoA
(Roche) were used in a final volume of 120 µl of incubation
reaction. CAT activity was determined in cell extracts by TLC
(Baker-flex; provided by J. T. Baker, Div. of Mallinckrodt Baker,
Phillipsburg, NJ, U.S.A.). The CAT activities were quantified by
densitometry (Image-Quant version 5.1; Molecular Dynamics,
Sunnyvale, CA, U.S.A.).
Northern-blot analysis

Total RNA was prepared using the RNeasy kit (Qiagen,
Valencia, CA, U.S.A.). Total RNA (8 µg) was electrophoresed on
formaldehyde agarose gels, and transferred to nylon membrane
(Hybond-N; Amersham Biosciences) as described previously
[31]. The probes were labelled with [32 P]dCTP (3000 Ci/mmol;
Amersham Biosciences) using the Rediprimer II kit (Amersham)
and hybridized in QuikHyb solution (Stratagene, La Jolla, CA,
U.S.A.) following the conditions described by the manufacturer.
The filters were exposed to X-ray film (Eastman Kodak,
Rochester, NY, U.S.A.) in cassettes with intensifying screens
(Kodak) at − 70 ◦ C.
EMSA (electrophoretic mobility-shift assay)

Confluent cells were washed with PBS and nuclear extracts were
prepared [25]. EMSA using nuclear extracts from human dermal
fibroblasts was performed as described previously [32]. Protein
concentration of the extracts was determined using the Bio-Rad
reagent. An 85 and a 46 bp DNA fragment (Figure 3A) were used
as probes in all EMSA experiments. The fragments were obtained
by PCR amplification employing the following primers: S9
at − 134 bp (5 -CTCCCAAATTGGGGGCCGGGC-3 ), S14 at
− 109 bp (5 -TGCCCCAGCCAATCAGAGCT-3 ) and S2
at − 50 bp (5 -AGGAACCCTGCCCCTCGGAGA-3 ) of the human COL1A1 promoter. Oligonucleotides containing consensus
sequences for Sp1 and for CBF were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, U.S.A.). Oligonucleotides for
Myb-binding site ‘tcgacacattaTAACGGttttttagc’ were obtained
from the Nucleic Acid Facility at Thomas Jefferson University
(Philadelphia, PA, U.S.A.). Radioactive probes were generated by
phosphorylating the 5 -ends with polynucleotide kinase (Roche)
and [γ -32 P]ATP (Amersham Biosciences). Binding reactions
containing 5–10 µg of nuclear extracts, 2 µg of poly (dI/dC)
and approx. 50 000 c.p.m. of (0.2 ng) radiolabelled probes were
incubated for 20 min at room temperature in a buffer containing
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40 mM KCl, 15 mM Hepes (pH 7.9), 1 mM EDTA, 0.2 mM
dithiothreitol, 1 mM MgCl2 and 5 % (v/v) glycerol in a total
volume of 20 µl. Sp1 and CBF antibodies for supershift assays
were obtained from Santa Cruz Biotechnology.
Immunodepletion

Nuclear extracts (100 µg) were incubated at 4 ◦ C for 1 h with
IgG, anti-HA (haemagglutinin)-B-Myb-antibody, Sp1, CBF-A or
CBF-B polyclonal antibodies and then for 1 h with Protein G-Plus
agarose conjugate. After centrifugation, supernatants were used
for EMSA. Immunoprecipitated proteins were washed four times
in a lysis buffer [20 mM Tris/HCl, pH 7.2/150 mM NaCl/0.1 %
Nonidet P40/10 % (v/v) glycerol/1 mM dithiothreitol/100 mM
sodium fluoride/10 µg/ml aprotinin, leupeptin and PMSF],
resolved by SDS/PAGE and blotted with the anti-HA-probe, antiB-Myb, anti-Sp1, anti-CBF-A and anti-CBF-B antibodies.
Immunoprecipitation/Western-blot analysis

Normal and SSc fibroblasts were lysed in the lysis buffer. Nuclear extracts were precleared with 30 µl of Protein G-Plus
agarose conjugate and immunoprecipitated with IgG, HA tag,
Sp1, CBF-A or CBF-B polyclonal antibodies (Santa Cruz Biotechnology) overnight at 4 ◦ C. Protein G-Plus (20 µl) agarose
conjugate was added and the samples were rocked for 1 h at 4 ◦ C.
After three washes, samples were electrophoresed on SDS/polyacrylamide gel and transferred to a PVDF-Plus membrane (MSI,
Westboro, MA, U.S.A.). Western-blot analysis was performed
with B-Myb N-19, B-Myb C-20 and Sp1 polyclonal antibodies
(Santa Cruz Biotechnology) in Blotto (5 % dry milk in PBS) plus
0.1 % Nonidet P40. After washings and incubation with secondary antibody coupled with peroxidase, the filter was developed
using a chemiluminescent substrate according to the manufacturer’s instructions (ECL® -plus, Amersham Biosciences).
RESULTS
B-Myb down-regulates the expression of COL1A1
in human dermal fibroblasts

To analyse the correlation between B-Myb and COL1A1 mRNA
expression in normal and SSc fibroblasts, Northern-blot analysis
was performed (Figure 1A). Serum-deprived (0.1 % FBS) quiescent cells were stimulated with 10 % FBS, and mRNA levels of
B-Myb and COL1A1 were analysed after 0, 24 and 48 h. B-Myb
mRNA reached its highest level of expression in both fibroblasts
after 24 h (lanes 2N and 2S), and then started decreasing at 48 h
when the cells were confluent. In contrast, COL1A1 mRNA levels
were higher (lanes 3N and 3S) with respect to the exponentially
growing cells (lanes 2N and 2S). The fact that no differences in
levels of COL1A1 expression between normal and SSc fibroblasts
were observed could be explained by the effects of serum depletion on the growth of the cells used in these studies. In the 48 h
sample 3S, when compared with the 3N sample, we did observe
a slight increase in mRNA levels.
To assess the effect of B-Myb on COL1A1 mRNA levels, the
full-length B-Myb cDNA was transfected into subconfluent SSc
fibroblasts for 48 h. Total RNA was isolated and Northern-blot
analysis was performed (Figure 1B). Decreased COL1A1 mRNA
expression was observed in B-Myb-transfected fibroblasts (lane 2)
compared with mock-transfected cells (lanes 1), without affecting
glyceraldehyde-3-phosphate dehydrogenase and ribosomal (28
and 18 S) RNA levels (results not shown). Similar results,
showing a decrease in COL1A1 expression using total RNA from

Figure 1 B-Myb down-regulates COL1A1 steady-state mRNA levels in
human dermal fibroblasts
(A) Northern-blot analysis demonstrating the inverse relationship of α1 (I) pro-collagen mRNA
(COL1A1) and that of B-Myb during cell proliferation. Normal and SSc fibroblasts were serumstarved with 0.1 % FBS for 48 h and stimulated with 10 % FBS for 0 h (lanes 1N and 1S), 24 h
(lanes 2N and 2S) and 48 h (lanes 3N and 3S). (B) Ectopic expression of the full-length B-Myb
cDNA by transient transfection in SSc fibroblasts correlated with decreased COL1A1 mRNA
levels. Northern-blot analysis was performed using total RNA (8 µg) from mock-transfected
(lane 1) and B-Myb transfected SSc fibroblasts (lane 2). In both experiments, a glyceraldehyde3-phosphate dehydrogenase cDNA probe was used as a loading control.

normal fibroblasts transfected and overexpressing the ectopic
B-Myb, were previously obtained [36]. These results, taken together, suggest that endogenous B-Myb expression (Figure 1A) and
ectopic B-Myb overexpression (Figure 1B) in dermal fibroblasts
down-regulate COL1A1 mRNA levels.
B-Myb down-regulates the activity of the proximal region
of the COL1A1 promoter

To determine the COL1A1 promoter region affected by B-Myb,
we co-transfected SSc fibroblasts with several CAT-containing
deletion constructs (− 2300, − 675, − 369, − 174 and − 84 bp) of
the human COL1A1 promoter region (Figure 2A) together with
either an expression vector containing the B-myb cDNA driven
by the CMV promoter or the CMV (no insert) control plasmid.
Figure 2(B) shows a representative duplicate experiment. We
identified a region between − 174 and − 84 bp of the proximal
COL1A1 promoter that was strongly down-regulated (up to
60 %) by B-Myb overexpression (Figure 2C). Moreover, we
also transfected COL1A1 deletion constructs containing more
distal regions of the promoter (− 5.3, − 4.0 and − 3.4 kb) and
confirmed that the down-regulation was restricted to the proximal
promoter region (results not shown). These results suggest that
B-Myb acts as a repressor of COL1A1 expression in human
dermal SSc fibroblasts at the transcriptional level by interacting
with the proximal promoter region of the gene.
Overexpression of B-Myb decreases the binding activity
of Sp1 and CBF in the COL1A1 proximal promoter

Sequence analysis of the COL1A1 promoter region affected by
B-Myb overexpression showed that it does not contain MBS.
This region, however, has been demonstrated to interact with
some other transcription factors (Figures 3A and 3B) such as
CBF, Sp1, Sp3 and NF-1 [25,33–35]. To examine whether B-Myb
could bind directly to this region, gel-shift assays were performed
using different fragments of the COL1A1 promoter (S9-S2 and
S9-S14, see Figure 3A) and a glutathione-S-transferase B-Myb
DNA-binding domain (GST-B-Myb-DBD) fusion protein [11],
but no retarded complexes were detected (results not shown).

c 2004 Biochemical Society

612

L. Cicchillitti and others

Figure 2 CAT assay demonstrating that overexpression of B-Myb is
correlated with a down-regulation of the COL1A1 proximal promoter activity
(A) Schematic representation of the COL1A1 promoter CAT constructs. (B) SSc fibroblasts
were co-transfected in duplicate with several CAT-containing deletion constructs of the human
COL1A1 promoter (− 2300, − 675, − 369, − 174 and − 84 bp) and the empty CMV vector
(−) or the CMV vector expressing B-Myb (+). Ch, [14 C]chloramphenicol; Ac, acetylated form of
[14 C]chloramphenicol. (C) Histograms represent the results of three different experiments, and
the error bars represent S.D. CAT activities, corrected for differences in transfection efficiencies,
are compared with the activity observed with the insertless plasmid (CMV), which was arbitrarily
set at 100 %.

Furthermore, gel shift using nuclear extracts from B-Myb or
mock-transfected SSc fibroblasts were performed. The results,
shown in Figure 3(B), suggest that B-Myb does not directly
interact with the COL1A1 proximal promoter since no additional
band(s) was observed when using nuclear extracts from cells
overexpressing B-Myb (lanes 4, 5 and 8) compared with the
mock-transfected fibroblasts (lanes 2, 3 and 7). In contrast, a
significant decrease in DNA-binding activity was observed for
Sp1 and CBF complexes (lanes 4, 5 and 8). In addition, a
faster migrating C2 complex, not yet identified, seems also to
be modulated by B-Myb overexpression, whereas a fainter C1
complex, also not yet identified, appears to be unaffected (lane 8).
Supershifted complexes using Sp1 and CBF (Figure 3C, lanes 2
and 3) antibodies in the proximal promoter region of COL1A1
are also shown. We have also noted a partial supershift for Sp1
(lane 2) showing a remaining band that could be due to a partial
shift of Sp1 or to another complex, most probably Sp3 for which
we have previously demonstrated binding in the same promoter
region [25]. Furthermore, we performed gel-shift assays using
B-Myb, Sp1 and CBF-specific consensus oligonucleotides and
nuclear extracts from B-myb or mock-transfected SSc fibroblasts
(Figure 3D). The DNA-binding activity of CBF and Sp1 to their
consensus sequences was decreased (approx. 40–60 %) when the
cells were transfected with B-Myb. The nuclear extracts from
B-Myb-transfected fibroblasts showed a much stronger binding
activity compared with the mock-transfected cells when the
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Figure 3 B-Myb decreases the binding activity of Sp1 and CBF to COL1A1
proximal promoter region
EMSAs were performed using the 85 bp or the 46 bp promoter fragments generated by PCR using
the S9-S2 or S9-S14 primers respectively. (A) Schematic diagram of the potential transcription
binding sites in the proximal COL1A1 promoter. (B) Nuclear extracts (NE) from SSc fibroblasts
transfected with the empty CMV vector (lanes 2, 3 and 7) and with the CMV vector expressing
the full-length B-Myb (lanes 4, 5 and 8) were incubated with the (S9-S2) 85 bp (lanes 2–5) and
(S9-S14) 46 bp (lanes 7 and 8) probes. Two different concentrations of NE (6 µg lanes 2, 4
and 12 µg lanes 3 and 5) were used with the (S9-S2) 85 bp probe. Note the marked decrease
(lanes 4 and 5) in Sp1 and CBF DNA-binding activity in NE from B-Myb-transfected SSc
fibroblasts compared with the mock-transfected cells. Lanes 1 and 6 contain probe alone,
(S9-S2) 85 bp and (S9-S14) 46 bp probes respectively. (C) EMSA using the 85 bp probe and
nuclear extracts from SSc fibroblasts (lane 1) and supershift analysis by using Sp1 (lane 2)
and CBF antibodies (lane 3) showing the protein–DNA complexes formed by the transcription
factors Sp1 and CBF in the proximal promoter region of COL1A1. Supershifted complexes are
denoted by the letter S. (D) B-MBS, Sp1 or CBF consensus oligonucleotides were used in
EMSA to test the binding efficiency of nuclear extracts from mock-transfected cells (−) and
from B-Myb-transfected cells (+).

specific B-MBS was used as a probe, confirming that transfected
B-Myb is functional (Figure 3D, top panel). The results suggest
that B-Myb does not bind directly to the DNA, but is capable of
inhibiting partially the binding of Sp1 and CBF to their consensus
sites in the COL1A1 proximal promoter region.
B-Myb interacts with the Sp1–CBF complex in immunodepleted
SSc fibroblast nuclear extracts

To assess whether B-Myb binds specifically to the DNA–protein
complex formed by Sp1 and CBF of the COL1A1 proximal
promoter region, we transfected the CMV-WT/B-Myb construct
encoding the full-length B-Myb fused to the HA tag into SSc
fibroblasts. Nuclear extracts from SSc fibroblasts overexpressing
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Figure 4 B-Myb interacts with the Sp1/CBF complex in immunodepleted
SSc fibroblast nuclear extracts
(A) EMSA using the 46 bp promoter fragment and nuclear extracts from HA-B-Myb-transfected
SSc fibroblasts pretreated with antibody to rabbit IgG (lanes 1 and 2) and HA-tagged antibody
(lanes 3 and 4). Two different concentrations of nuclear extracts (6 and 12 µg) were used.
(B) EMSA using the 46 bp promoter fragment and Sp1 (lanes 3 and 4) or CBF-B (lanes 5 and 6)
immunodepleted (ID) fractions. Lanes 1 and 2 represent nuclear fractions pretreated with αIgG
as control.

HA-B-Myb were depleted of B-Myb using HA antibody and
tested in EMSA with the S9–S14 32 P-labelled 46 bp probe (Figure 4A). The results show that pretreatment with the HA antibody
decreased the formation of the retarded DNA–protein complex
formed by Sp1 and CBF (lanes 3 and 4) compared with the fraction
incubated with an antibody to IgG (lanes 1 and 2), suggesting that
the B-Myb-immunodepleted nuclear extracts were also partially
deprived of Sp1 and CBF. The specificity of the decrease in Sp1and CBF-binding efficiency was confirmed using the same probe
with the Sp1- or CBF-immunodepleted fractions (Figure 4B,
lanes 3–6). The supernatant and pellet fractions were then tested
for B-Myb, Sp1 and CBF by Western blot to confirm effective
depletion from the fractions used for EMSA (results not shown).
As demonstrated in Figure 4(B), the Sp1-immunodepleted fraction also shows a decrease in CBF-binding (lanes 3 and 4) and the
CBF-immunodepleted fraction shows a decrease in Sp1 binding
(lanes 5 and 6), suggesting the occurrence of a physical interaction
between Sp1 and CBF, already demonstrated in rat fatty acid
synthase, the human metalloproteinase-2 and natriuretic receptor
genes [37–39].
B-Myb, Sp1 and CBF co-immunoprecipitate in SSc fibroblasts

To investigate further, whether B-Myb interacts in vivo with Sp1
and/or CBF transcription factors, immunoprecipitation assays
were performed using nuclear extracts from SSc fibroblasts with
or without transfection of the CMV-B-Myb construct expressing
the full-length B-Myb fused to the HA tag. The nuclear extracts
(100 µg) were incubated with either IgG, HA, Sp1, CBF-A or
CBF-B antibodies (Figures 5A and 5B) and the samples were electrophoresed on an SDS/polyacrylamide gel. Western blotting using antibodies against B-Myb demonstrated that the Sp1, CBF-A,
CBF-B and HA (as control) were positive for B-Myb (Figure 5A, lanes 3, 5, 7 and 9) and negative for IgG immunoprecipitate (lane 1). In fact, B-Myb was positive only in the unbound
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B-Myb physically interacts with Sp1 and CBF in SSc fibroblasts

(A) Nuclear extracts were prepared from SSc fibroblasts and 100 µg were used for each immunoprecipitated with IgG (lane 1) Sp1 (lane 3), CBF-A (lane 5) and CBF-B (lane 7) antibodies. In
lane 9, cells were transfected with HA-B-Myb and immunoprecipitated with HA tag, as positive
control. The membrane was probed with B-Myb antibody, and both endogenous (lanes 2, 3,
5 and 7) and exogenous B-myb (lanes 9 and 10) proteins were detected. (B) SSc fibroblast
nuclear extracts were immunoprecipitated with IgG (lane 1), HA (lane 3), CBF-A (lane 5), CBF-B
(lane 7) and Sp1 (lane 9) antibodies. The membrane was probed with Sp1 antibody. In lane 2,
cells were transfected with HA-B-Myb and immunoprecipitated with HA antibody. As indicated in
(A, B), lanes 2, 4, 6, 8 and 10 represent the unbound fractions of the respective immunoprecipitated antibody reactions.

IgG fraction (lane 2) and negative in all the other fractions (lanes 4,
6 and 8), except lane 10, where B-Myb was overexpressed using
the HA-B-Myb construct. We have also found interaction between
B-Myb and Sp1 when the HA-B-Myb immunoprecipitate was
probed with the Sp1 antibody (Figure 5B, lane 3). In addition, we
detected interaction of the CBF-A (lane 5) and CBF-B (lane 7)
immunoprecipitates with Sp1, confirming a physical interaction
between Sp1 and CBF as previously demonstrated for other genes
[37–39]. Also, as described in Figure 5(A), the interaction for the
IgG fraction was only in the unbound immunoprecipitate (Figure 5B, lane 2). We also observed that Sp1 was recognized in
the unbound immunoprecipitate fractions of HA, CBF-A, CBF-B
and Sp1 (lanes 4, 6, 8 and 10). This result could be explained by
the excess of SSc nuclear extracts (100 µg) used in each reaction
and/or to the high amount of Sp1 protein present in SSc fibroblasts
[28].
B-Myb down-regulates COL1A1 expression through its C-terminal
domain in SSc fibroblasts

To determine which region(s) of B-Myb (Figure 6A) was required
for the modulation of COL1A1, the transactivation domains
of two C-terminal truncated forms encoding amino acids 1–
508 (Sca/B-Myb) or amino acids 1–350 (Eco/B-Myb) and an
N-terminal truncated cDNA (N/B-Myb) that lacks the DNAbinding domain repeats were analysed for their effects on the
COL1A1 proximal promoter. The wild-type and mutated forms
of B-myb were tested for their expression in SSc fibroblasts
(Figure 6B) and co-transfected into SSc fibroblasts with the − 174
COL1A1 promoter construct and CAT assays performed (Figure 6C). Our results showed > 50 % decrease in COL1A1
promoter activity compared with mock-transfected cells (CMV),
when the full-length B-Myb (B-Myb) or the N-terminal-deleted
form of B-Myb (N/B-Myb) was co-transfected with the
− 174 bp deleted construct promoter (Figures 6C and 6D). In
contrast, no change in COL1A1 promoter activity was observed
when the B-Myb mutants (Eco/B-Myb or Sca-B-Myb) lacking
the C-terminal domain were overexpressed (Figures 6C and 6D).
It is possible that the C-terminal B-Myb mutants are expressed
at lower levels compared with the wild-type protein (Figure 6B,
lanes 2–4). However, the N-terminal mutant (lane 5) is expressed
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B-Myb down-regulates COL1A1 promoter activity through its C-terminal domain

(A) Schematic representation of the full-length B-Myb and the deletion mutants of B-Myb. (B) Western blot showing cellular extracts from mock-transfected cells (lane 1), full-length B-Myb (lane 2)
and mutated forms, Eco/B-Myb (lane 3) and Sca/B-Myb (lane 4) and N/B-Myb (lane 5) overexpressed in SSc fibroblasts. (C) The − 174 deletion CAT construct of the human COL1A1 promoter
was co-transfected in duplicate with empty vector (CMV) or with CMV vector containing the cDNA for WT/B-Myb, N/B-Myb, Eco/DNA or Sca/DNA. The COL1A1 promoter activity decreased
when the cDNA of WT/B-Myb or of N/B-Myb was employed. No effects were observed when B-Myb cDNAs deleted for the C-terminal domain Sca/B-Myb and Eco/B-Myb were used (+). Ch,
[14 C]chloramphenicol; Ac, acetylated form of [14 C]chloramphenicol. (D) Histograms represent the results of three different experiments. Error bars represent S.D.

at lower or similar levels than the C-terminal mutants, yet its
activity is similar to that of wild-type B-Myb (Figures 6C and
6D). Thus expression levels of the B-Myb C-terminal mutants do
not explain their loss of function. These results indicate that the
region of B-Myb involved in the down-regulation of COL1A1
could be localized, only within the C-terminal of the protein.

DISCUSSION

In the present study, we have demonstrated that the transcription
factor B-Myb inhibits the expression of the COL1A1 gene
in human dermal fibroblasts. We have localized the inhibitory
activity within 174 bp of the transcription start site of the
COL1A1 promoter region. Furthermore, we have shown that
B-Myb decreases Sp1 and CBF binding to their specific binding
sites situated in the same region. Using SSc nuclear extracts,
we found a physical interaction between B-Myb and Sp1
and CBF transcription factors that may be responsible for the
down-regulatory effects on COL1A1 expression. We have also
determined that the region of B-Myb involved in this modulation
is contained within the C-terminal domain of the protein.
Genes encoding the α1 (COL1A1) and α2 (COL1A2) chains
of type I collagen are expressed in different cell types at
distinct stages of development and under several physiological
conditions [40,41]. Excessive production of type I collagen is
a key feature of fibrotic disorders of the lung, liver, kidney,
skin and heart, and diseases such as SSc and hypertension,
often leading to severe organ dysfunction [26,42,43]. Increased
collagen deposition is a central event in the pathogenesis of SSc,
but the mechanisms responsible for the pathological increase in
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the expression of collagen genes in SSc have not been clearly
defined [22,26]. Previous studies suggested that, in addition to
enhanced extracellular production and deposition, an abnormality
of fibroblast growth might contribute to the fibrotic lesions [42].
The levels of COL1A1 mRNA are low in cultures of exponentially
growing SMCs and increase as the cells reach confluence, whereas
the levels of B-Myb mRNA expression are high in proliferating
cells [19,20]. Piccinini et al. [44] have shown that B-Myb is
expressed in proliferating SSc fibroblasts and its expression peaks
24 h after serum starvation, as has been found in the present
study (Figure 1). The same authors have observed that c-Myb,
but not B-Myb, up-regulates type I collagen expression [45], and
that B-Myb may partially inhibit transactivation of the COL1A2
promoter driven by c-Myb [46]. These results suggest that B-Myb
and c-Myb may exert opposite effects through the repression or
activation of the same gene(s).
In the present study, we focused on the assessment of regulation
of B-Myb of COL1A1 in human SSc fibroblasts. It has already
been shown that B-Myb overexpression induces a strong downregulation (90 %) of the COL1A1 and COL1A2 collagen gene
promoters in bovine aortic SMCs [19]. Here, we demonstrated that
B-Myb expression is inversely correlated with that of COL1A1 in
normal and SSc fibroblasts (Figure 1A). The fact that no apparent
increase in COL1A1 levels was seen in SSc versus normal
fibroblasts could be due to the conditions of serum starvation
or to a random variation of COL1A1 RNA levels among different
SSc fibroblasts as we have previously observed [47]. The 174 bp
COL1A1 promoter sequence that contains binding sites for CBF,
Sp1 and other transcription factors, mediates maximal promoter
activity of the COL1A1 promoter in human dermal fibroblasts
[25,28]. Absence of MBSs in the 174 bp promoter region and up

B-Myb acts as a repressor of human COL1A1

to − 2000 bp (present study and [46]) suggests that the effect of
B-Myb on COL1A1 expression does not occur by means of a direct protein–DNA interaction (Figure 3), but, instead, through a
possible interaction of B-Myb with the DNA–protein complex
formed by Sp1 and CBF (Figures 4 and 5). In addition, we
found that Sp1 and CBF interact with each other, as previously
shown [37–39], and B-myb may cause destabilization of these
two positive factors positioned only 15 bp apart in the COL1A1
promoter (Figure 3).
Therefore two distinct mechanisms may be responsible for
down-modulation of COL1A1 and COL1A2 genes and probably
work in concert to decrease collagen I production in dermal
fibroblasts. The first mechanism has been described by other
groups [45,46], and may involve direct B-Myb binding to
its consensus sequence in the COL1A2 promoter, resulting in
squelching of other active Myb family members, such as c-Myb
[46]. The other mechanism, described in this study, proposes a
direct physical interaction between B-Myb and the CBF–Sp1
complex (Figures 4 and 5), which could be responsible for
B-Myb-mediated reduction of Sp1 and CBF binding to their
DNA-consensus sequences (Figure 3), and decreased COL1A1
transcription (Figures 2 and 6). So far, no direct binding of B-Myb
to the COL1A2 promoter has been reported, despite the presence
of MBSs [46]. The C-terminal domain of B-Myb has been shown
to contain a conserved region with significant homology to other
members of the myb gene family. The conserved region has been
shown to be critical for transactivation by B-Myb, presumably
via the binding of cofactors involved in the modification and
activation of B-Myb [48]. In agreement with these observations,
the analysis of the region of B-Myb involved in the down-modulation of COL1A1 indicates that the C-terminal region of B-Myb,
but not the DNA-binding domain, is essential for this activity
(Figure 6). Previously, we reported that B-Myb co-operates with
the transcription factor Sp1, resulting in the synergistic activation
of the B-Myb promoter in SAOS 2 osteosarcoma cells [32]. In
the light of the results described here, we hypothesize that B-Myb
and the Sp1–CBF complex are involved in either co-operative
or antagonistic interactions, depending on the promoter and/or
cellular context.
In conclusion, B-Myb probably contributes to the regulation of
COL1A1 expression in SSc as well as normal dermal fibroblasts
and may exert its effect by decreasing Sp1 and CBF binding to
their specific sites in the proximal promoter region. Analysis of
the role of post-transcriptional modification of B-Myb, such as
phosphorylation and acetylation, and their role in the mechanistic
interaction occurring among B-Myb, Sp1 and CBF are worth
further investigation. Elucidation of the modes of action of regulatory factors of extracellular matrix proteins is essential towards
understanding pathological fibrotic processes, such as SSc.
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